Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 04 March 2013 | By Louise Zornoza
A new report released by China's State Food and Drug Administration's (FDA) Center for Drug Evaluation shows that review and approval times for clinical trial applications for most drugs averages about 8 months per products, while oncology products fare the best at five months.
The report, released 28 February 2013, also noted that "the gap between the time-to-market of imported drugs at home and abroad also significantly shortened" relative to years prior.
The SFDA encourages Chinese clinical trial sponsors to conduct global trials and has a policy of accelerating the review and approval of such applications. The report also notes that original research conducted with imported drugs targets China's unmet medical needs and facilitates public access to the latest world-class therapies.
The agency said it utilizes the rational allocation of its review resources "to shorten the time-to-market at home and abroad for drugs with important clinical value."
Tags: Report, SFDA, pharmaceutical, clinical trial, drug